Abstract
Tuberculosis (TB) continues to be a major global challenge, claiming about two million deaths each year. The emergence of drug resistance due to high incidence of poor patient compliance has further worsened the situation. Targeted delivery of drugs to macrophage, the site of Mycobacterium tuberculosis infection and replication, has been shown to have implications as a promising option in TB treatment. A variety of biocompatible and biodegradable polymer-based carrier-based delivery systems have emerged as potential drug delivery systems (DDS). Such targeted delivery systems have been shown to have significant merits over free drug, including improved drug bioavailability, limiting adverse drug effects and requiring less frequent administration regimes and lowering drug doses. The pulmonary administration of inhalable dry powders incorporating multiple drugs has particularly exhibited encouraging results against MDR-TB, and is expected to shorten the treatment duration, thereby improving patient compliance. Recently, the administration of pulmonary drug delivery as an adjunct to existing oral treatment regimens has been shown to achieve sufficient drug concentrations in certain systemic compartments and thus further enhance treatment effectiveness. The present chapter discusses the recent research updates on carriers used in preclinical or clinical studies against TB, the challenges associated, and future perspectives.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Ahmad, S. (2010). Pathogenesis, immunology, and diagnosis of latent Mycobacterium tuberculosis infection. Clinical & Developmental Immunology, 2011, 814943.
Ahmad, Z., Sharma, S., & Khuller, G. K. (2007). Chemotherapeutic evaluation of alginate nanoparticle-encapsulated azole antifungal and antitubercular drugs against murine tuberculosis. Nanomedicine: Nanotechnology, Biology and Medicine, 3(3), 239–243.
Ahmad, Z., Pandey, R., Sharma, S., & Khuller, G. K. (2008). Novel chemotherapy for tuberculosis: Chemotherapeutic potential of econazole-and moxifloxacin-loaded PLG nanoparticles. International Journal of Antimicrobial Agents, 31, 142–146.
Ahmad, Z., Maqbool, M., & Raja, A. F. (2011). Nanomedicine for tuberculosis: Insights from animal models. International Journal of Nano Dimension, 2(1), 67–84.
Ahmed, M. M., Velayati, A. A., & Mohammed, S. H. (2016). Epidemiology of multidrug-resistant, extensively drug resistant, and totally drug resistant tuberculosis in Middle East countries. International Journal of Mycobacteriology, 5(3), 249–256.
Chan, J. G. Y., Wong, J., Zhou, Q. T., Leung, S. S. Y., & Chan, H. K. (2014). Advances in device and formulation technologies for pulmonary drug delivery. AAPS PharmSciTech, 15(4), 882–897.
D’Ambrosio, L., Centis, R., Tiberi, S., Tadolini, M., Dalcolmo, M., Rendon, A., et al. (2017). Delamanid and bedaquiline to treat multidrug-resistant and extensively drug-resistant tuberculosis in children: A systematic review. Journal of Thoracic Disease, 9(7), 2093–2101.
Deol, P., & Khuller, G. K. (1997). Lung specific stealth liposomes: Stability, biodistribution and toxicity of liposomal antitubercular drugs in mice. Biochimica et Biophysica Acta (BBA) – General Subjects, 1334(2–3), 161–172.
Deretic, V., Via, L. E., Fratti, R. A., & Deretic, D. (1997). Mycobacterial phagosome maturation, Rab proteins and intracellular trafficking. Electrophoresis, 18(14), 2542–2547.
Dharmadhikari, A. S., Kabadi, M., Gerety, B., Hickey, A. J., Fourie, P. B., & Nardell, E. (2013). Phase I, single-dose, dose-escalating study of inhaled dry powder capreomycin: A new approach to therapy of drug-resistant tuberculosis. Antimicrobial Agents and Chemotherapy, 57(6), 2613–2619.
Fernstrom, A., & Goldblatt, M. (2013). Aerobiology and its role in the transmission of infectious diseases. J Pathogens, 2013, 493960.
Flannagan, R. S., Jaumouille, V., & Grinstein, S. (2012). The cell biology of phagocytosis. Annual Review of Pathology, 7, 61–98.
Garcia-Contreras, L., Padilla-Carlin, D. J., Sung, J., VerBerkmoes, J., Muttil, P., Elbert, K., & Hickey, A. (2017). Pharmacokinetics of ethionamide delivered in spray-dried microparticles to the lungs of Guinea pigs. Journal of Pharmaceutical Sciences, 106(1), 331–337.
Grace, A. G., Mittal, A., Jain, S., Tripathy, J. P., Satyanarayana, S., Tharyan, P., & Kirubakaran, R. (2018). Shortened treatment regimens versus the standard regimen for drug-sensitive pulmonary tuberculosis. The Cochrane Library.
Guirado, E., Schlesinger, L. S., & Kaplan, G. (2013, September). Macrophages in tuberculosis: Friend or foe. In: Seminars in immunopathology (Vol. 35, No. 5, pp. 563–583). Springer: Berlin/Heidelberg.
Hanif, S. N. M., & Garcia-Contreras, L. (2012). Pharmaceutical aerosols for the treatment and prevention of tuberculosis. Frontiers in Cellular and Infection Microbiology, 2, 118.
Hickey, A. J., Durham, P. G., Dharmadhikari, A., & Nardell, E. A. (2016). Inhaled drug treatment for tuberculosis: Past progress and future prospects. Journal of Controlled Release, 240, 127–134.
Hirota, K., & Terada, H. (2014). Particle-manufacturing technology-based inhalation therapy for pulmonary diseases. In H. Ohshima & K. Makino (Eds.), Colloid and interface science in pharmaceutical research and development (Vol. 2014, Ist ed., pp. 103–119). Oxford: Elsevier.
Hoffmann, H., Kohl, T. A., Hofmann-Thiel, S., Merker, M., Beckert, P., Jaton, K., Nedialkova, L., Sahalchyk, E., Rothe, T., Keller, P. M., & Niemann, S. (2016). Delamanid and bedaquiline resistance in Mycobacterium tuberculosis ancestral Beijing genotype causing extensively drug-resistant tuberculosis in a Tibetan refugee. American Journal of Respiratory and Critical Care Medicine, 193(3), 337–340.
Hou, S., Wu, J., Li, X., & Shu, H. (2015). Practical, regulatory and clinical considerations for development of inhalation drug products. Asian Journal of Pharmaceutical Sciences, 10(6), 490–500.
Kahnert, A., Seiler, P., Stein, M., Bandermann, S., Hahnke, K., Mollenkopf, H., & Kaufmann, S. H. (2006). Alternative activation deprives macrophages of a coordinated defense program to Mycobacterium tuberculosis. European Journal of Immunology, 36(3), 631–647.
Kaur, J., Muttil, P., Verma, R. K., Kumar, K., Yadav, A. B., Sharma, R., & Misra, A. (2008). A hand-held apparatus for “nose-only” exposure of mice to inhalable microparticles as a dry powder inhalation targeting lung and airway macrophages. European Journal of Pharmaceutical Sciences, 34(1), 56–65.
Kendall, E. A., Azman, A. S., Cobelens, F. G., & Dowdy, D. W. (2017). MDR-TB treatment as prevention: The projected population-level impact of expanded treatment for multidrug-resistant tuberculosis. PLoS One, 12(3), e0172748.
Kerantzas, C. A., & Jacobs, W. R. (2017). Origins of combination therapy for tuberculosis: Lessons for future antimicrobial development and application. MBio, 8(2), e01586-16.
Kunda, N. K., Wafula, D., Tram, M., Wu, T. H., & Muttil, P. (2016). A stable live bacterial vaccine. European Journal of Pharmaceutics and Biopharmaceutics, 103, 109–117.
Kvasnovsky, C. L., Peter, C. J., & Van dW. M. L. (2016). Treatment outcomes for patients with extensively drug-resistant tuberculosis, KwaZulu-Natal and Eastern cape provinces, South Africa. Emerging Infectious Diseases, 22(9), 1529–1536.
Lee, J. Y. (2015). Diagnosis and treatment of extrapulmonary tuberculosis. Tuberculosis Respiratory Disease, 78(2), 47–55.
Legentil, L., Paris, F., Ballet, C., Trouvelot, S., Daire, X., Vetvicka, V., & Ferrières, V. (2015). Molecular interactions of β-(1→ 3)-glucans with their receptors. Molecules, 20(6), 9745–9766.
Malcomson, R. J., & Embleton, J. K. (1998). Dry powder formulations for pulmonary delivery. Pharmaceutical Science & Technology Today, 1(9), 394–398.
Matteelli, A., Roggi, A., & Carvalho, A. C. (2014). Extensively drug-resistant tuberculosis: Epidemiology and management. Clinical Epidemiology, 6, 111–118.
Miller, J. B., Abramson, H. A., & Ratner, B. (1950). Aerosol streptomycin treatment of advanced pulmonary tuberculosis in children. American Journal of Diseases of Children, 80(2), 207–237.
Mitragotri, S. (2005). Immunization without needles. Nature Reviews. Immunology, 5(12), 905–916.
Muttil, P., Kaur, J., Kumar, K., Yadav, A. B., Sharma, R., & Misra, A. (2007). Inhalable microparticles containing large payload of anti-tuberculosis drugs. European Journal of Pharmaceutical Sciences, 32(2), 140–150.
Muttil, P., Wang, C., & Hickey, A. J. (2009). Inhaled drug delivery for tuberculosis therapy. Pharmaceutical Research, 26(11), 2401–2416.
Nasiruddin, M., Neyaz, M., & Das, S. (2017). Nanotechnology-based approach in tuberculosis treatment. Tuberculosis Research and Treatment, 2017. Article ID 4920209, 12 (Review).
O’Garra, A., Redford, P. S., McNab, F. W., Bloom, C. I., Wilkinson, R. J., & Berry, M. P. (2013). The immune response in tuberculosis. Annual Review of Immunology, 31, 475–527.
Pai, M., Behr, M. A., Dowdy, D., Dheda, K., Divangahi, M., Boehme, C. C., Ginsberg, A., Swaminathan, S., Spigelman, M., Getahun, H., Menzies, D., & Raviglione, M. (2016). Tuberculosis. Nature Reviews. Disease Primers, 2, 16076. 1–23.
Pandey, R., Sharma, S., & Khuller, G. K. (2005). Oral solid lipid nanoparticle-based antitubercular chemotherapy. Tuberculosis, 85(5–6), 415–420.
Parikh, R., Patel, L., & Dalwadi, S. (2014). Microparticles of rifampicin: Comparison of pulmonary route with oral route for drug uptake by alveolar macrophages, phagocytosis activity and toxicity study in albino rats. Drug Delivery, 21(6), 406–411.
Parumasivam, T., Chang, R. Y. K., Abdelghany, S., Ye, T. T., Britton, W. J., & Chan, H. K. (2016). Dry powder inhalable formulations for anti-tubercular therapy. Advanced Drug Delivery Reviews, 102, 83–101.
Petersen, E., Maeurer, M., Marais, B., Migliori, G. B., Mwaba, P., Ntoumi, F., et al. (2017). World TB day 2017: Advances, challenges and opportunities in the “end-TB” era. International Journal of Infectious Diseases, 56, 1–5.
Pham, D. D., Fattal, E., & Tsapis, N. (2015). Pulmonary drug delivery systems for tuberculosis treatment. International Journal of Pharmaceutics, 478(2), 517–529.
Pinheiro, M., Lúcio, M., Lima, J. L., & Reis, S. (2011). Liposomes as drug delivery systems for the treatment of TB. Nanomedicine, 6(8), 1413–1428.
Prasad, R., Singh, A., Balasubramanian, V., & Gupta, N. (2017). Extensively drug-resistant tuberculosis in India: Current evidence on diagnosis & management. The Indian Journal of Medical Research, 145(3), 271–293.
Price, D. N., Kunda, N. K., & Muttil, P. (2018). Challenges associated with the pulmonary delivery of therapeutic dry powders for preclinical testing. Kona Powder and Particle Journal, 36, 2019008.
Qurrat-ul-Ain, Sharma, S., Khuller, G., & Garg, S. K. (2003). Alginate based oral drug delivery system for tuberculosis: Pharmacokinetics and therapeutic effects. The Journal of Antimicrobial Chemotherapy, 51(4), 931–938.
Raviglione, M., & Sulis, G. (2016). Tuberculosis 2015: Burden, challenges and strategy for control and elimination. Infectious Disease Reports, 8(2), 6570.
Rom, W. N., & Garay, S. M. (2003). Tuberculosis (2nd ed.). Philadelphia, PA: Lippincott Williams & Wilkins.
Sacks, L. V., Pendle, S., Orlovic, D., Andre, M., Popara, M., Moore, G., Thonell, L., & Hurwitz, S. (2001). Adjunctive salvage therapy with inhaled aminoglycosides for patients with persistent smear-positive pulmonary tuberculosis. Clinical Infectious Diseases, 32(1), 44–49.
Sen, H., Jayanthi, S., Sinha, R., Sharma, R., & Muttil, P.. (2003). Inhalable biodegradable microparticles for target-specific drug delivery in tuberculosis and a process thereof. PCT/IB03/04694.
Sharma, R., Saxena, D., Dwivedi, A. K., & Misra, A. (2001). Inhalable microparticles containing drug combinations to target alveolar macrophages for treatment of pulmonary tuberculosis. Pharmaceutical Research, 18(10), 1405–1410.
Sharma, R., Yadav, A. B., Muttil, P., Kajal, H., & Misra, A. (2011). Inhalable microparticles modify cytokine secretion by lung macrophages of infected mice. Tuberculosis, 91(1), 107–110.
Shegokar, R., Al Shaal, L., & Mitri, K. (2011). Present status of nanoparticle research for treatment of tuberculosis. Journal of Pharmacy & Pharmaceutical Sciences, 14(1), 100–116.
Sotgiu, G., Centis, R., D’ambrosio, L., & Migliori, G. B. (2015). Tuberculosis treatment and drug regimens. Cold Spring Harbor Perspectives in Medicine, 5(5), a017822.
Soto, E., Kim, Y. S., Lee, J., Kornfeld, H., & Ostroff, G. (2010). Glucan particle encapsulated rifampicin for targeted delivery to macrophages. Polymers, 2(4), 681–689.
Thomas, S., & Bagyalakshmi, J. (2013). Design, development and characterization of pyrazinamide niosomal dosage form. American Journal of PharmTech Research, 3(6), 532–544.
Tiberi, S., Scardigli, A., Centis, R., D’Ambrosio, L., Munoz-Torrico, M., Salazar-Lezama, M. A., Spanevello, A., Visca, D., Zumla, A., Migliori, G. B., & Luna, J. A. C. (2017). Classifying new anti-tuberculosis drugs: Rationale and future perspectives. International Journal of Infectious Diseases, 56, 181–184.
Turner, M. T., Haskal, R., McGowan, K., Nardell, E., & Sabbag, R. (1998). Inhaled kanamycin in the treatment of multidrug-resistant tuberculosis: A study of five patients. Infectious Diseases in Clinical Practice, 7(1), 49–53.
Upadhyay, T. K., Fatima, N., Sharma, D., Saravanakumar, V., & Sharma, R. (2017). Preparation and characterization of beta-glucan particles containing a payload of nanoembedded rifabutin for enhanced targeted delivery to macrophages. EXCLI Journal, 16, 210–228.
Uplekar, M., Weil, D., Lonnroth, K., Jaramillo, E., Lienhardt, C., Dias, H. M., et al. (2015). WHO’s new end TB strategy. The Lancet, 385, 1799–1801.
Verma, R. K., Singh, A. K., Mohan, M., Agrawal, A. K., & Misra, A. (2011). Inhaled therapies for tuberculosis and the relevance of activation of lung macrophages by particulate drug-delivery systems. Therapeutic Delivery, 2(6), 753–768.
Verma, R. K., Germishuizen, W. A., Motheo, M. P., Agrawal, A. K., Singh, A. K., Mohan, M., Gupta, P., Gupta, U. D., Cholo, M., Anderson, R., Fourie, P. B., & Fourie, P. B. (2013a). Inhaled microparticles containing clofazimine are efficacious in treatment of experimental tuberculosis in mice. Antimicrobial Agents and Chemotherapy, 57(2), 1050–1052.
Verma, R., Khanna, P., & Mehta, B. (2013b). Revised national tuberculosis control program in India: The need to strengthen. International Journal of Preventive Medicine, 4(1), 1–5.
WHO. (2017). Guidelines for treatment of drug-susceptible tuberculosis and patient care (2017 update). http://www.who.int/tb/publications/2017/dstb_guidance_2017/en/. Accessed 25 Mar 2018.
World Health Organization. Global tuberculosis report 2017. WHO/HTM/TB/2017.23. Geneva: World Health Organization. 2017, 21–63.
Zumla, A. I., Gillespie, S. H., Hoelscher, M., Philips, P. P., Cole, S. T., Abubakar, I., McHugh, T. D., Schito, M., Maeurer, M., & Nunn, A. J. (2014). New antituberculosis drugs, regimens, and adjunct therapies: Needs, advances, and future prospects. The Lancet Infectious Diseases, 14(4), 327–340.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Singapore Pte Ltd.
About this chapter
Cite this chapter
Upadhyay, T.K., Sharma, A., Fatima, N., Singh, A., Muttil, P., Sharma, R. (2019). Targeted Delivery of Antibiotics Using Microparticles to Combat Multidrug-Resistant Tuberculosis. In: Ahmad, I., Ahmad, S., Rumbaugh, K. (eds) Antibacterial Drug Discovery to Combat MDR. Springer, Singapore. https://doi.org/10.1007/978-981-13-9871-1_20
Download citation
DOI: https://doi.org/10.1007/978-981-13-9871-1_20
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-13-9870-4
Online ISBN: 978-981-13-9871-1
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)